IL1B and type 2 diabetes mellitus: Recent positive clinical results from a small trial with high affinity anti-human IL-1β (XOMA 052) also support targeting IL-1β mediated inflammatory damage to pancreatic beta cells as a potential therapeutic approach for type 2 diabetes [20].